Acquisition Momentum The company recently expanded its capacity and market reach by acquiring Radcal, strengthening its US footprint and radiation imaging capabilities. This signals openness to strategic partnerships and cross-sell opportunities with Radcal customers and legacy IBA Dosimetry users.

Integrated QA Growth With the ongoing development and deployment of the myQA iON platform and enhanced myQA Machines environments, there is a clear focus on integrated QA workflows. This offers opportunities to upsell platform licenses, modules, and services to radiotherapy centers seeking end-to-end QA solutions.

Global Footprint Headquartered in Germany with subsidiaries in the US and China indicates a global go-to-market strategy. This creates potential for region-specific demonstrations, localized support packs, and channel partnerships to accelerate sales in North America, Europe, and Asia-Pacific.

Diversified Imaging Expansion into X-ray imaging through Radcal and established QA for both radiotherapy and diagnostic imaging suggests cross-sell potential to hospitals and clinics needing both QA instrumentation and imaging markers, increasing average deal size.

Financial Scale Current revenue range is modest ($1M–$10M) with a mid-size employee base. This implies readiness for scalable, multi-year procurement contracts, service agreements, and training programs that can grow alongside customer adoption without large upfront commitments.